menu
    • menu
    [{"orgOrder":0,"company":"Wanbang Biopharmaceuticals","sponsor":"Sirona Biochem Corp","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"TFC-039","moa":"SGLT2","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Wanbang Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Wanbang Biopharmaceuticals \/ Wanbang Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Wanbang Biopharmaceuticals \/ Wanbang Biopharmaceuticals"},{"orgOrder":0,"company":"Wanbang Biopharmaceuticals","sponsor":"Regent Pacific","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"||Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Wanbang Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Wanbang Biopharmaceuticals \/ Wanbang Biopharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Wanbang Biopharmaceuticals \/ Wanbang Biopharmaceuticals"},{"orgOrder":0,"company":"Wanbang Biopharmaceuticals","sponsor":"Wanbang Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Dun Ye Guan Xin Ning","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Wanbang Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Wanbang Biopharmaceuticals \/ Wanbang Biopharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Wanbang Biopharmaceuticals \/ Wanbang Biopharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Wanbang Biopharmaceuticals

    Menu

    Wanbang Biopharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Wanbang Biopharmaceuticals

                            China arrow
                            AAPS
                            Not Confirmed

                            Wanbang Biopharmaceuticals

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TFC-039

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Recipient : Sirona Biochem Corp

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals

                            Details : Under the agreement, Wanbang obtained the rights to develop the SGLT2 inhibitor, TFC-039 as a diabetes treatment in China and Sirona retained the global rights. SGLT2 inhibitors provide an opportunity to treat inflicted animals with an oral medication.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 23, 2022

                            Lead Product(s) : TFC-039

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Recipient : Sirona Biochem Corp

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Wanbang Biopharmaceuticals

                            China arrow
                            AAPS
                            Not Confirmed

                            Wanbang Biopharmaceuticals

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lidocaine,Prilocaine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Recipient : Regent Pacific

                            Deal Size : $4.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Regent Pacific's Strategic Partner Receives Approval from NMPA to Submit IND Application

                            Details : Under the License Agreement Regent Pacific is now entitled to receive a payment of approximately HK$6.24 million from Wanbang Pharmaceutical, which is payable within 30 business days. NMPA will now formally review Senstend™ for Clinical Trial Approval.

                            Product Name : Senstend

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 02, 2020

                            Lead Product(s) : Lidocaine,Prilocaine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Recipient : Regent Pacific

                            Deal Size : $4.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Wanbang Biopharmaceuticals

                            China arrow
                            AAPS
                            Not Confirmed

                            Wanbang Biopharmaceuticals

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dun Ye Guan Xin Ning

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Recipient : Peking University First Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Dun Ye Guan Xin Ning Tablet in Patients With Stable Angina Pectoris

                            Details : Dun Ye Guan Xin Ning is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Coronary Disease.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            June 23, 2017

                            Lead Product(s) : Dun Ye Guan Xin Ning

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Peking University First Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth